Announced details
TOHO HOLDINGS CO.,LTD. made the investment through the CVC fund “TOHO Ventures.” The limited partner of TOHO Ventures is TOHO HOLDINGS CO.,LTD.
Based in London, UK, with Robert Johnson as its representative, the company was established in October 2020. It develops next-generation targeted protein degraders for neurodegenerative diseases such as Alzheimer’s disease.
London, UK
The impact is currently immaterial. Over the medium to long term, the investment is expected to contribute to increasing the corporate value of the Toho Holdings Group.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | SELFTAC® platform, Next-generation targeted protein degradation (TPD) drugs |
| Counterparty | Oyster Therapeutics Limited |
| Counterparty overview | Based in London, UK, with Robert Johnson as its representative, the company was established in October 2020. It develops next-generation targeted protein degraders for neurodegenerative diseases such as Alzheimer’s disease. |
| Relationship with the Company | TOHO HOLDINGS CO.,LTD. made the investment through the CVC fund “TOHO Ventures.” The limited partner of TOHO Ventures is TOHO HOLDINGS CO.,LTD. |
| Applicable area | Alzheimer's disease, Neurodegenerative diseases such as Parkinson’s disease, Drug Discovery |
| Location | London, UK |
| Impact on Business Performance | The impact is currently immaterial. Over the medium to long term, the investment is expected to contribute to increasing the corporate value of the Toho Holdings Group. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The investment was made based on the assessment of the technological innovation of Oyster Therapeutics’ “SELFTAC®” platform, its strategic potential in neurodegenerative diseases such as Alzheimer’s disease, and the expertise of its management team, which has experience in drug discovery and commercialization.